This company has a solution to drug price gouging — and a new target (IMMY, RTRX)
AP Photo/Richard Drew
Mark Baum thrust himself into drug-price debate last year when he offered to make a $1 version of Daraprim, the toxoplasmosis treatment that Martin Shkreli was selling for $750 a pill.
Now Baum has a new target in his sights.
Called Thiola, the drug also treats a rare disease and is owned by a company that hiked its price substantially — by 2000% in 2014 — without any real justification.
And, in fact, the architect of Thiola's price hike was none other than Shkreli. Читать дальше...